Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | CA3 | P07451 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.64 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716931 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL10683800 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL10685206 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL13010044 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL11475528 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL10688529 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL10690536 | 1.00 | EPHX1 (1.00) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL1389225 | 0.98 | EPHX1 (0.96) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL2736707 | 0.91 | EPHX1 (0.84) | EPHX1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7545639 | 0.89 | EPHX1 (0.80) | EPHX1MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | claimed |
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | AM CHEMICALS LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | AM CHEMICALS LLC (US) | 2018-01-18 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2006-07-20 | — | — | US | disclosed |
| US-4719312-A | FLUOROALKYLAMINES | MERCK & CO., INC. (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0009944-B1 | LYSOSOMOTROPIC FLUORINATED AMINE THERAPEUTIC AGENTS AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| EP-0009944-A2 | Lysosomotropic fluorinated amine therapeutic agents and compositions containing them | MERCK & CO. INC. (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781175-B2 | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates | NCL, PAICS, RTCB | EPHX1 3410/4885MEN1 2389/4885KMT2A 1607/4885 |
| US-20060160763-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | EPHX1 3307/4885MEN1 1982/4885KMT2A 4420/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | EPHX1 3307/4885MEN1 1982/4885KMT2A 4420/4885 |
| US-20180016232-A1 | SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES | NCL, PAICS, RTCB | EPHX1 3410/4885MEN1 2389/4885KMT2A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.